Xue-Song Fu1, Ping-Ping Li. 1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Integrated Traditional Chinese and Western Medicine, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing 100142, China.
Abstract
OBJECTIVE: Estradiol (E2) plays an important role in the development of breast cancer. In postmenopausal women, the estrogen can be synthesized via aromatase (CYP19) pathway and steroid-sulfatase (STS) pathway in peripheral tissues, when the production in ovary has ceased. The objective of our study was to explore the effects of Shu-Gan-Liang-Xue Decoction (SGLXD) on the expressions of CYP19 and STS in estrogen receptor positive breast cancer MCF-7 and T47D cells. METHODS: The effects of SGLXD on the cell viability of MCF-7 and T47D were analyzed by MTT assay. By quantitative real-time RT-PCR and Western blot, we evaluated the mRNA and protein expressions of CYP19 and STS in MCF-7 and T47D cells after SGLXD treatment. RESULTS: By MTT assay, the cell viability rates of MCF-7 and T47D were significantly inhibited by SGLXD in a dose-dependent manner, the IC50 values were 40.07 mg/ml for MCF-7 cells and 25.62 mg/ml for T47D cells, respectively. As evidenced by real-time PCR and Western blot, the high concentrations of SGLXD significantly down-regulated the expressions of CYP19 and STS both in the transcript level and the protein level. CONCLUSION: The results suggest that SGLXD is a potential dual aromatase-sulfatase inhibitor by simultaneously down-regulating the expressions of CYP19 and STS in MCF-7 and T47D cells.
OBJECTIVE: Estradiol (E2) plays an important role in the development of breast cancer. In postmenopausal women, the estrogen can be synthesized via aromatase (CYP19) pathway and steroid-sulfatase (STS) pathway in peripheral tissues, when the production in ovary has ceased. The objective of our study was to explore the effects of Shu-Gan-Liang-Xue Decoction (SGLXD) on the expressions of CYP19 and STS in estrogen receptor positive breast cancer MCF-7 and T47D cells. METHODS: The effects of SGLXD on the cell viability of MCF-7 and T47D were analyzed by MTT assay. By quantitative real-time RT-PCR and Western blot, we evaluated the mRNA and protein expressions of CYP19 and STS in MCF-7 and T47D cells after SGLXD treatment. RESULTS: By MTT assay, the cell viability rates of MCF-7 and T47D were significantly inhibited by SGLXD in a dose-dependent manner, the IC50 values were 40.07 mg/ml for MCF-7 cells and 25.62 mg/ml for T47D cells, respectively. As evidenced by real-time PCR and Western blot, the high concentrations of SGLXD significantly down-regulated the expressions of CYP19 and STS both in the transcript level and the protein level. CONCLUSION: The results suggest that SGLXD is a potential dual aromatase-sulfatase inhibitor by simultaneously down-regulating the expressions of CYP19 and STS in MCF-7 and T47D cells.
Entities:
Keywords:
Aromatase (CYP19); Breast cancer; Shu-Gan-Liang-Xue Decoction (SGLXD); Steroid-sulfatase (STS)
Authors: Julie E Reed; L W Lawrence Woo; James J Robinson; Bertrand Leblond; Mathew P Leese; Atul Purohit; Michael J Reed; Barry V L Potter Journal: Biochem Biophys Res Commun Date: 2004-04-23 Impact factor: 3.575
Authors: Paul M Wood; L W Lawrence Woo; Anna Humphreys; Surinder K Chander; Atul Purohit; Michael J Reed; Barry V L Potter Journal: J Steroid Biochem Mol Biol Date: 2005-02-05 Impact factor: 4.292
Authors: Hatem A M Hejaz; L W Lawrence Woo; Atul Purohit; Michael J Reed; Barry V L Potter Journal: Bioorg Med Chem Date: 2004-05-15 Impact factor: 3.641
Authors: Andreas Billich; Josef G Meingassner; Peter Nussbaumer; Sandrine Desrayaud; Charles Lam; Anthony Winiski; Erwin Schreiner Journal: J Steroid Biochem Mol Biol Date: 2004-09 Impact factor: 4.292